Osteoporosis
Conditions
Interventions
Risedronate(2 years)
Risedronate +vitaminK2(2 years)
Sponsors
Japan Osteoporosis Society/A-TOP consortium
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Criteria for initiation of pharmacotherapy to prevent fragility fracture(Japanese Guidelines for the prevention and treatment of osteoporosis 2006 edition) 2.Age>=65 years old(female) 3.Risk factor number for incident fracture>=1(in A-TOP research group) 4.Possible to walk alone 5.Possible to answer QOL questionnaire
Exclusion criteria
Exclusion criteria: 1.Using warfarin 2.Secondary osteoporosis and low bone mass disease except osteoporosis 3.Having contraindication in using drugs 4.Hypothyroidism and hyperparathyroidism 5.Disfunction of communication of the intention 6.Prevalent vertebral fracture>=6 7.Deformation of vertebra 8.Abnormal heart function,abnormal hepatic function,abnormal kidney function 9.Taken bisphosphonate within previous 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incident vertebral fracture rate and incident nonvertebral fracture rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral density,stature,QOL, undercarboxylated osteocalcin,safety | — |
Countries
Japan
Contacts
Public ContactYoji Mitadera
Public health research foundation CSP-A-TOP
Outcome results
None listed